180-181 / 671
Flaire after discontinuation of TKI
•
Some patients with
EGFR-mutant lung cancer and acquired resistance
to erlotinib or gefitinib
(RECIST progression after initial benefit) have
accelerated progression of disease after discontinuation of TKI
•
14/61 patients experienced a disease flair with a median of 8 days
(range 3–21) after discontinuation